Shionogi-ViiV Healthcare: 572 HIV Drug Shows Potent Antiviral Activity

22nd Jul 2010 13:30

LONDON (Dow Jones)-- Shionogi-ViiV Healthcare LLC, announced Thursday data from two Phase IIb studies showing that its once-daily, unboosted investigational HIV integrase inhibitor, S/GSK1349572 or '572, exhibited potent antiviral activity in treatment-naive HIV subjects as well as in treatment-experienced subjects resistant to raltegravir or RAL. MAIN FACTS: -There remains a significant need for additional medicines that can help address the complex treatment issues for HIV, and also help simplify treatment regimens for patients. -As a once-daily, unboosted integrase inhibitor, '572 could provide an important therapy for patients living with HIV -The company plans to confirm the safety and efficacy of this compound in Phase III studies, which are expected to begin by the end of the year. -By Zechariah Hemans, Dow Jones Newswires; 44-20-7842-9411; [email protected] (END) Dow Jones Newswires July 22, 2010 08:30 ET (12:30 GMT)